药物发现
业务
转化研究
损耗
药物开发
制药工业
风险分析(工程)
数据科学
透视图(图形)
计算机科学
医学
药品
药理学
生物技术
生物信息学
生物
人工智能
牙科
作者
Lorna Ewart,Adrian Roth
标识
DOI:10.1038/d41573-020-00030-2
摘要
Using human-relevant, translational in vitro models is widely considered to reduce attrition during drug discovery and development. Despite this, the adoption of models based on microphysiological systems — organs-on-chips or organoids — by pharma companies is moderate at best, and realizing the full potential of these models will need greater collaboration between stakeholders. Using human-relevant, translational in vitro models is widely considered to reduce attrition during drug discovery and development. Despite this, the adoption of models based on microphysiological systems — organs-on-chips or organoids — by pharma companies is moderate at best, and realizing the full potential of these models will need greater collaboration between stakeholders.
科研通智能强力驱动
Strongly Powered by AbleSci AI